Background. Infectious diseases (ID) consultation and antimicrobial stewardship intervention have been shown to improve the management of Staphylococcus aureus bacteremia (SAB). As the workload of antimicrobial stewardship programs (ASPs) continues to increase, ASPs must find a way to maximize the efficiency of the program while optimizing patient outcomes. The objective of this study was to evaluate the impact of incorporating health informatics into the management of SAB via a pharmacist-driven initiative.
Bacteremia is the most well recognized and clinically important manifestation of infection due to Staphylococcus aureus [1] . Despite this recognition and increased clinical cognizance, the overall mortality rate associated with S. aureus bacteremia (SAB) has not decreased over the last few decades [2] . Numerous studies have documented the important role of infectious diseases (ID) consultation and adherence to quality-of-care process measures in the management of SAB. These investigations reveal that ID consultation undoubtedly optimizes the care of patients with SAB, including several publications documenting a reduction in mortality rates [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] .
Although the results of these studies are encouraging, obligatory ID consultation for all patients with SAB may not be logistically applicable or practical in all healthcare settings. This is especially true in the current healthcare era given the dramatic and consistent decreases in the number of physicians considering ID as a specialty [15] . In contrast, the number of antimicrobial stewardship programs (ASPs) is increasing worldwide [16] and the implementation of an ASP is now mandatory in all US hospitals [17] . Numerous studies have demonstrated the clinical and economic benefits of ASPs across various disease states [18] , and a recent study observed improved adherence to performance measures and a reduction in 30 day readmissions associated with ASP intervention in patients with SAB [19] .
As ASPs develop and continue to reach for higher-hanging fruit, it is imperative to find methods to maximize the efficiency of the program. Technological advances including electronic medical records (EMR) and clinical decision support systems (CDSS) allow ASPs to deliver higher-quality, more efficient patient care [20] . Incorporating health informatics allows ASPs to more seamlessly integrate the immense amount of data arising from clinical, microbiological, and evidence-based sources to optimize patient outcomes. Additionally, expanding the ownership of ASP interventions and engaging prescribers [21] and frontline members [22, 23] of the healthcare team allow ASPs to increase the breadth and proficiency of their interventions. The objective of this study was to evaluate the impact of an automated, pharmacist-driven targeted initiative for patients with SAB.
MATERIALS AND METHODS

Study Design
This was a retrospective, quasi-experimental study of all hospitalized adult (18-89 years of age) inpatients with a blood culture positive for S. aureus admitted from January 2015 to March 2015 (pre-intervention period) and January 2016 to March 2016 (intervention period) to The Ohio State University Wexner Medical Center (OSUWMC), a 1367 bed tertiary care facility located in Columbus, Ohio. The study was approved by the Office of Responsible Research Practices Institutional Review Board, with a waiver of consent granted. Only the first episode of SAB per patient was analyzed during the study period. Patients who were incarcerated, received an ID consult prior to positive blood culture for S. aureus, were transferred from an outside hospital with ongoing SAB on admission, or were discharged prematurely against medical advice were excluded.
Microbiology and Informatics Workflow
Blood cultures were incubated via BD BACTECT 9240 system (Becton-Dickinson, Sparks, Maryland). Aliquots from bottles that signaled positive were Gram stained and sub-cultured to appropriate media. If the Gram stain indicated the presence of a Gram positive organism, an aliquot of blood was loaded into the Verigene Gram positive blood culture (BC-GP) assay (Nanosphere, Northbrook, IL) for identification of S. aureus and detection of mecA [24] . This assay was completed in realtime and results were communicated to the patient's treating physician by microbiology laboratory personnel within 10 minutes during both the pre-intervention and intervention periods. During the intervention period, service-based pharmacists were also notified of the result of the BC-GP assay every 15 minutes around the clock through the use of a patient scoring tool via the EMR. This tool was developed by a project team consisting of 3 informatics pharmacists (Director of Pharmacy Informatics, Senior System Analyst, and Pharmacy Informatics Resident) and 2 ID pharmacists within our institution and was designed to trigger based on the specific text string reported into the patient's laboratory record by the BC-GP system ("Staphylococcus aureus DNA Detected"). Once the alert was triggered, the patient was assigned the maximum point value possible within the scoring tool prompting the pharmacist to perform dedicated review and intervention, as appropriate.
The scoring tool also displayed patients' demographic data and relevant infection-related information including microbiology results and antimicrobials administered. Additionally, the scoring tool linked to a prepopulated progress note template within the EMR that allowed pharmacists to provide standardized written communication to the patient's treating clinician as part of the patient's permanent medical record. Final organism identification and susceptibilities were analyzed with the Microscan WalkAway System (Siemens Diagnostics, Los Angeles, California) or Etest® (bioMerieux, Durham, North Carolina). Definitive organism and identification and susceptibility testing results were reported in the EMR without additional active notification.
Pharmacist Intervention
Prior to the implementation of the automated pharmacist-driven intervention, an evidence-based practice guideline for the diagnosis and management of SAB was available to clinicians. The guideline was developed by a multidisciplinary team consisting of physicians, pharmacists, and quality of care practitioners. The ASP evaluated patients with SAB and performed interventions as appropriate on a case-by-case basis. However, there was no formal, system-wide process to actively promote adherence to SAB quality-of-care measures or encourage ID consultation. On December 15, 2015, the Department of Pharmacy launched a coordinated go-live of the patient scoring tool for SAB and a 1-hour continuing education lecture session devoted to familiarizing the staff with the institution's evidence-based comprehensive care bundle for the management of SAB. The SAB bundle was developed following a literature review and included process measures aligned with the Infectious Diseases Society of America (IDSA) methicillinresistant S. aureus (MRSA) quality-of-care performance measures [25] . All clinical pharmacists throughout the hospital then received real-time notifications for every blood culture positive for S. aureus via the patient scoring tool described previously. Standardized recommendations based on the institution's SAB evidenced-based practice guideline ( Figure 1 ) were communicated by the pharmacist to the treating physician both verbally and through a written progress note in the EMR.
Pharmacists were required to evaluate the patient scoring tool list at least once per shift to identify any patients with a score assigned. There are three 8-hour shifts within the Pharmacy Department, with the third shift being an overnight shift. There are at least 2 clinical generalist pharmacists staffing during each shift. Clinical pharmacy specialists are only available during the first shift. These pharmacists evaluated all patients with SAB and provided verbal and written recommendations to the treating physician to promote compliance with quality-of-care components. For MSSA bacteremia, the most effective therapy was defined as continuous infusion cefazolin or nafcillin. For MRSA bacteremia, vancomycin was considered to be effective therapy unless the patient met the OSUWMC ASP criteria for vancomycin failure, at which time daptomycin was recommended. Vancomycin failure was defined as positive blood cultures for MRSA ≥5 days with therapeutic vancomycin troughs (15-20 µg/ mL), all known sources removed, and/or vancomycin minimum inhibitory concentration ≥2 µg/mL. For patients with prior history of MRSA bacteremia treated with vancomycin within the previous 90 days, daptomycin was recommended up front. Pharmacists at OSUWMC have authority to enter a verbal medication order into the computerized order entry system with subsequent co-signature by a physician. Privileged pharmacists have an expanded scope of practice that allows them, once the prescriber has made a diagnosis and initiated treatment, to leverage their clinical expertise to order pertinent laboratory tests and use the results of those tests to adjust medication therapy [26] . This privileging does not include ordering antimicrobial therapy or diagnostic tests, such as blood cultures or echocardiograms, and only applies once the diagnosis has been made and treatment has been initiated by the prescriber.
Data and Outcomes
Data obtained included age, sex, hospital service, comorbidities including: diabetes, chronic kidney disease, receipt of immunosuppressive therapy (defined as cytotoxic agents, corticosteroids at a dosage of ≥15 mg of prednisone equivalence daily for >1 week within 4 weeks, anti-rejection medications within 2 weeks, or absolute neutrophil count <500 cells/mm 3 ), lung disease, congestive heart failure, liver disease, or solid organ or bone marrow transplant, presence of implanted prosthesis, type of prosthesis, history of intravenous drug abuse, hospitalization in the previous 90 days, antibiotics in the previous 90 days, SAB in the previous 90 days, source of SAB, S. aureus methicillin susceptibility, hospital or community SAB acquisition, intensive care unit admission at time of blood culture collection. The primary outcome was overall compliance along with adherence to individual quality-of-care components. The components evaluated were ID consult, repeat blood cultures, echocardiogram, and initiation of SAB-targeted antimicrobial treatment. These components were study-specific and did not directly reflect the performance measures in the IDSA guidelines for MRSA [25] , although our institutional evidence-based practice guideline (Figure 1 ) encompassed all IDSA recommendations. Targeted therapy was defined as antimicrobial therapy initiated in response to the identification of S. aureus by the BC-GP assay. Time to targeted therapy was assessed as the difference between initiation of empiric therapy and initiation of targeted therapy. For all other components, the time was calculated from the date of the BC-GP assay result and the date of which the repeat blood culture, echocardiogram, or ID consult occurred. Secondary outcomes included time to pharmacist intervention, duration of bacteremia, length of hospital stay (LOS), infection-related LOS, 30-day readmission, and 30-day all-cause mortality. Time to pharmacist intervention was calculated as the difference between the time BC-GP signaled positive for S. aureus and pharmacist documentation in the EMR. Duration of bacteremia was calculated as the difference between the first positive blood culture and the first negative blood culture. LOS was calculated as the difference between admission and discharge date. Infection-related LOS was calculated as the difference between initiation of antibiotic administration for SAB and antibiotic discontinuation or discharge date, whichever was sooner.
Statistical Analysis
Comparisons of categorical data were performed using χ 2 or
Fisher exact test, as appropriate. Comparisons of continuous data were performed using a Student t test or Mann-Whitney U test, as appropriate. A 2-tailed significance of <0.05 was considered statistically significant. All statistical analyses were performed by using SPSS, version 22 (SPSS Inc., Chicago, IL).
RESULTS
During the study period, 84 patients were identified for study inclusion, 45 in the pre-intervention and 39 in the intervention group. The primary reason for exclusion was receipt of an ID consultation prior to SAB (Figure 2 ). Demographics and baseline characteristics were well matched between the 2 groups (Table 1) , although patients in the intervention group were significantly younger and had a lower incidence of chronic lung disease. The majority of patients were admitted to a medical service and had at least 1 comorbid condition. Most had been admitted to the hospital in the previous 3 months, but less than half had received any antibiotics. Approximately a quarter of the patients in each group had some type of implanted prosthesis and almost twice as many in the intervention group had a history of intravenous drug abuse. The most common source of SAB was catheter-related with only three patients having an endovascular source of infection, all of which were in the intervention group. Methicillin-resistant S. aureus was the responsible pathogen in over half of the episodes of bacteremia in both groups and approximately two-thirds and three-fourths of the SAB occurrences were community-acquired in the pre-intervention and intervention groups, respectively. During the study period, documented pharmacist intervention occurred in an average (±SD) of 8.8 ± 7.8 hours from the time of BC-GP assay positivity, approximately 8-24 hours sooner than any other endpoint. All patients in both the pre-intervention and intervention group had empiric antimicrobial treatment initiated, the vast majority of which was vancomycin ( Table 2 ). The incidence of ID consult improved significantly by almost 20% in the intervention group (75.6% vs 94.9%, P = .015). There were no significant differences observed in the number of patients who had repeat blood cultures or an echocardiogram ordered between the 2 groups. As a whole, all 4 quality-of-care components for the management of SAB were significantly more frequently adhered to in the intervention group (68.9% vs 92.3%; P = .008) ( Table 2 ). All 39 patients in the intervention group had targeted SAB therapy initiated compared to 84.4% in the pre-intervention group (P = .013), and this occurred a median of almost 40 hours sooner in the intervention group (91.8 [17.3-722] vs 54.3 [9.5-239.9], P = .079) ( Table 3 ). In terms of clinical outcomes, there were no differences in duration of bacteremia, LOS, infection-related LOS, or readmission between the groups. The all-cause mortality was 6-fold higher in the pre-intervention group compared to the intervention group (15.6% vs 2.6%, P = .063).
DISCUSSION
To our knowledge, this is the first study to evaluate the impact of an automated pharmacist-driven initiative for the management of SAB. This intervention significantly improved the overall adherence to important quality of care standards for patients with SAB. Implementation of a pharmacist-driven intervention Congestive heart failure 10 (22) 4 (10) .240
Liver disease 6 (13) 8 (21) .398
Solid organ transplant 0 (0) 3 (8) .096
Bone marrow transplant 0 (0) 0 (0) 1.00 Data presented as mean ± SD or n (%).
Abbreviations: MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; SD, standard deviation. in patients with SAB also resulted in a significant increase in the number of patients receiving an ID consult and targeted antibiotic therapy. Importantly, our study did not specifically evaluate an ASP program and its ability to impact patient care or mandatory ID consultation for SAB, which has been previously established. We sought to increase the breadth and efficiency of our ASP program by leveraging our EMR and incorporating our frontline pharmacists in providing disease state-based interventions for SAB.
Other published studies have evaluated the use of a comprehensive care bundle driven by either ASP or ID on the management of SAB. Nguyen and colleagues evaluated the impact of an antimicrobial stewardship-led comprehensive bundle for patients with SAB [19] . Overall bundle adherence to quality performance measures improved from 56.1% (46/82) in the pre-intervention group to 84.1% (74/88) in the ASPintervention group (P < .001). No significant differences in clinical outcomes were observed. Two other studies evaluated the impact of a bundle approach on the management of SAB with the use of ID physicians. Lopez-Cortes and colleagues demonstrated improved adherence to a quality-of-care indicator bundle among 12 hospitals in Spain, which resulted in a reduction in 14-day mortality (17.8% vs 11.3%; P = .04) [27] . Borde and colleagues conducted a single-center study of 59 cases and also found that a bundle approach increased adherence to bundle endpoints and decreased in-hospital mortality in patients with SAB [28] . A recent meta-analysis confirmed these findings with an overall 30-day mortality of 19.95% (95% confidence interval [CI] 14.37-27.02) with a significant difference in favor of ID consultation (12.39% vs 26.07%) [29] . In addition, the appropriateness of antistaphylococcal agent (relative risk [RR] 1.14 [95% CI 1.08-1.20]), follow-up blood cultures (RR 1.35 [95% CI 1.25-1.46]), and echocardiography (RR 1.98 [95% CI 1.66-2.37]) were performed more frequently following ID consultation. Our study is in contrast to the previously published studies in that we evaluated a pharmacist-driven scoring system for the management of SAB. We were able to demonstrate that, regardless of specialty or involvement in an ASP, all pharmacists were able to evaluate the patient's EMR and provide guideline-based recommendations for the management of SAB, resulting in improved compliance with performance measures.
Limitations to our study include those inherent to the retrospective study design, such as the inability to definitively assign causality for process measure compliance. Given the published data, we felt that encouraging an ID consult must be a fundamental part of our quality-of-care initiative for patients with SAB. Additionally, our study included a small sample size and was a single-center, nonrandomized design. The Department of Pharmacy determined it was imperative to provide a timely and comprehensive analysis of the effect of pharmacist-driven interventions on patient outcomes for SAB. Pharmacists were only required to review the patient scoring tool once per shift, but a significant impact on overall adherence to performance measures was still observed. Pharmacists did not record the amount of time required to make recommendations and interventions. However, the relative infrequency of SAB (approximately 1 new patient per day) made the workload manageable. Finally, we observed large disparities in some clinical endpoints, such as mortality, although our sample size was too small to statistically elucidate this outcome. This is the first study to demonstrate the impact of an automated, pharmacist-driven intervention for the management of patients with SAB. Importantly, our study did not directly utilize the resources of our ASP but expanded upon our ASP's reach by involving technology and non-ID trained pharmacists. We were able to demonstrate a significant improvement in patients receiving an ID consult, targeted antimicrobial therapy, and adherence to all SAB quality-of-care measures. As antimicrobial stewardship becomes a mandatory aspect of healthcare in all hospitals in the United States, ASPs will be forced to find ways to provide more efficient, impactful, disease state-based patient care. Our study provides the framework for and data to support this intervention in one of the most clinically important infectious diseases syndromes, SAB. Abbreviation: LOS, length-of-stay.
Notes
